These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8833669)

  • 1. Quantitative mapping of platinum and essential trace metal in cisplatin resistant and sensitive human ovarian adenocarcinoma cells.
    Ortega R; Moretto P; Fajac A; Benard J; Llabador Y; Simonoff M
    Cell Mol Biol (Noisy-le-grand); 1996 Feb; 42(1):77-88. PubMed ID: 8833669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The direct mapping of the uptake of platinum anticancer agents in individual human ovarian adenocarcinoma cells using a hard X-ray microprobe.
    Ilinski P; Lai B; Cai Z; Yun W; Legnini D; Talarico T; Cholewa M; Webster LK; Deacon GB; Rainone S; Phillips DR; Stampfl AP
    Cancer Res; 2003 Apr; 63(8):1776-9. PubMed ID: 12702562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
    Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
    Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Establishment of human ovarian cancer cisplatin resistant cell line COC1/DDP and its mechanism of resistance].
    Zhou Y; Chen H; Yang Q
    Zhonghua Yi Xue Za Zhi; 1996 Sep; 76(9):680-3. PubMed ID: 9275551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
    Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
    Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.
    Le Moguen K; Lincet H; Deslandes E; Hubert-Roux M; Lange C; Poulain L; Gauduchon P; Baudin B
    Proteomics; 2006 Oct; 6(19):5183-92. PubMed ID: 16941573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line.
    Naredi P; Heath DD; Enns RE; Howell SB
    Cancer Res; 1994 Dec; 54(24):6464-8. PubMed ID: 7987844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
    Andrews PA; Velury S; Mann SC; Howell SB
    Cancer Res; 1988 Jan; 48(1):68-73. PubMed ID: 3335000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.
    Bible KC; Boerner SA; Kirkland K; Anderl KL; Bartelt D; Svingen PA; Kottke TJ; Lee YK; Eckdahl S; Stalboerger PG; Jenkins RB; Kaufmann SH
    Clin Cancer Res; 2000 Feb; 6(2):661-70. PubMed ID: 10690552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant.
    Chau Q; Stewart DJ
    Cancer Chemother Pharmacol; 1999; 44(3):193-202. PubMed ID: 10453720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
    Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
    Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The differential expression of cytokeratin 18 in cisplatin-sensitive and -resistant human ovarian adenocarcinoma cells and its association with drug sensitivity.
    Parekh HK; Simpkins H
    Cancer Res; 1995 Nov; 55(22):5203-6. PubMed ID: 7585575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells.
    Zisowsky J; Koegel S; Leyers S; Devarakonda K; Kassack MU; Osmak M; Jaehde U
    Biochem Pharmacol; 2007 Jan; 73(2):298-307. PubMed ID: 17097621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
    Samimi G; Howell SB
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines.
    Yan XD; Pan LY; Yuan Y; Lang JH; Mao N
    J Proteome Res; 2007 Feb; 6(2):772-80. PubMed ID: 17269733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.